Innoviva Cash Flow from Investing Activities 2010-2024 | INVA
Innoviva cash flow from investing activities from 2010 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
Innoviva Annual Cash Flow Investing
(Millions of US $) |
| 2024 |
$-64 |
| 2023 |
$-67 |
| 2022 |
$-57 |
| 2021 |
$44 |
| 2020 |
$-315 |
| 2019 |
$-18 |
| 2018 |
$4 |
| 2017 |
$-23 |
| 2016 |
$-5 |
| 2015 |
$159 |
| 2014 |
$-65 |
| 2013 |
$-220 |
| 2012 |
$-58 |
| 2011 |
$-56 |
| 2010 |
$-40 |
| 2009 |
$2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.132B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
